Method of Predicting Non-Response to First Line Chemotherapy

The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor.

Attached files:


Patents:
US 20,100,184,065

Inventor(s): YEATMAN TIMOTHY J [US]; AGRAWAL DEEPAK [US]; DAUD ADIL [US]

Type of Offer: Licensing



« More Diagnostic Patents

---